title: Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model.
abstract: This study aims to examine the contribution of PEG-conjugated hemoglobin combined with cisplatin to the expression of HIF-1α and MDR1 in a tumor xenograft model. Cervical carcinoma models were assigned to 4 groups and treated respectively: group 1(control); group 2, cisplatin; group 3, PEG-Hb; group 4 cisplatin plus PEG-Hb. 4 weeks later, tumor volume and MVD was significantly decreased in group 4 compared with other groups. Lower expression of HIF-1α and MDR1 were detected in group4. Taken together, our data indicated that PEG-Hb plus cisplatin can promote tumor tissue oxygenation and enhance the chemotherapy sensitivity. HIF-1α regulated MDR1 pathway correlated with this process.
authors.affiliation: Institute of Microcirculation, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), Key Laboratory of Microcirculation Ministry of Health, Beijing, China.
authors.forename: Jianqun
authors.initials: J
authors.lastname: Han
authors.forename: Minhua
authors.initials: M
authors.lastname: Yu
authors.forename: Min
authors.initials: M
authors.lastname: Dai
authors.forename: Hongwei
authors.initials: H
authors.lastname: Li
authors.forename: Ruijuan
authors.initials: R
authors.lastname: Xiu
authors.forename: Qian
authors.initials: Q
authors.lastname: Liu
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001802:Blood Substitutes / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006367:HeLa Cells; D006454:Hemoglobins / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D051379:Mice; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D012996:Solutions; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D001802:Blood Substitutes; D006454:Hemoglobins; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C109960:PEG-hemoglobin; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D012996:Solutions; D011092:Polyethylene Glycols; D002945:Cisplatin